Bellevue Group Ag Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Bellevue Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$83.14 - $145.99 $3.26 Million - $5.72 Million	-39,207 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$110.08 - $142.92 $132,096 - $171,503	1,200 Added 3.16%	39,207 $4.65 Million
Q4 2021 Feb 10, 2022	BUY	$99.73 - $148.48 $2.05 Million - $3.04 Million	20,507 Added 117.18%	38,007 $5.24 Million
Q3 2021 Nov 12, 2021	SELL	$98.85 - $138.91 $1.83 Million - $2.57 Million	-18,500 Reduced 51.39%	17,500 $2.43 Million
Q1 2021 May 12, 2021	BUY	$64.07 - $91.75 $1.51 Million - $2.16 Million	23,500 Added 188.0%	36,000 $2.46 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $780,839 - $1.18 Million	-12,000 Reduced 48.98%	12,500 $1.07 Million
Q3 2020 Nov 16, 2020	BUY	$59.04 - $77.95 $1.45 Million - $1.91 Million	24,500 New	24,500 $1.59 Million
Q2 2020 Aug 13, 2020	SELL	$29.01 - $74.23 $719,448 - $1.84 Million	-24,800 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$27.51 - $57.29 $57,771 - $120,309	2,100 Added 9.25%	24,800 $844,000
Q4 2019 Feb 14, 2020	BUY	$40.86 - $57.65 $927,522 - $1.31 Million	22,700 New	22,700 $1.24 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.